JP2020505448A - ハンチントン病の治療のためのＰＰＡＲγアゴニスト - Google Patents

ハンチントン病の治療のためのＰＰＡＲγアゴニスト Download PDF

Info

Publication number
JP2020505448A
JP2020505448A JP2019559015A JP2019559015A JP2020505448A JP 2020505448 A JP2020505448 A JP 2020505448A JP 2019559015 A JP2019559015 A JP 2019559015A JP 2019559015 A JP2019559015 A JP 2019559015A JP 2020505448 A JP2020505448 A JP 2020505448A
Authority
JP
Japan
Prior art keywords
subject
disease
huntington
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019559015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505448A5 (enExample
Inventor
バーバラ フィンク
バーバラ フィンク
ローレンス ステインマン
ローレンス ステインマン
Original Assignee
コヒラス・バイオサイエンシズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コヒラス・バイオサイエンシズ・インコーポレイテッド filed Critical コヒラス・バイオサイエンシズ・インコーポレイテッド
Publication of JP2020505448A publication Critical patent/JP2020505448A/ja
Publication of JP2020505448A5 publication Critical patent/JP2020505448A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019559015A 2017-01-18 2018-01-18 ハンチントン病の治療のためのＰＰＡＲγアゴニスト Pending JP2020505448A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762447741P 2017-01-18 2017-01-18
US62/447,741 2017-01-18
PCT/US2018/014240 WO2018136635A1 (en) 2017-01-18 2018-01-18 Pparϒ agonist for the treatment of huntington's disease

Publications (2)

Publication Number Publication Date
JP2020505448A true JP2020505448A (ja) 2020-02-20
JP2020505448A5 JP2020505448A5 (enExample) 2021-02-25

Family

ID=62908392

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019559015A Pending JP2020505448A (ja) 2017-01-18 2018-01-18 ハンチントン病の治療のためのＰＰＡＲγアゴニスト

Country Status (13)

Country Link
US (1) US20190350918A1 (enExample)
EP (1) EP3570841A4 (enExample)
JP (1) JP2020505448A (enExample)
KR (1) KR20190122664A (enExample)
CN (1) CN110461330A (enExample)
AU (1) AU2018210165A1 (enExample)
BR (1) BR112019014529A2 (enExample)
CA (1) CA3050104A1 (enExample)
EA (1) EA201991716A1 (enExample)
IL (1) IL268008A (enExample)
MX (1) MX2019008535A (enExample)
SG (1) SG11201906644YA (enExample)
WO (1) WO2018136635A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895541B2 (en) * 2002-09-04 2014-11-25 James A. Carnazza Methods for inhibiting the development of huntington's disease
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
JP2008515978A (ja) * 2004-10-13 2008-05-15 ユニバーシティ オブ コネチカット カンナビネルジック脂質リガンド
WO2009097996A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
WO2010040055A2 (en) * 2008-10-03 2010-04-08 Intekrin Therapeutics, Inc. Oral pharmaceutical formulations for antidiabetic compounds
EP2448412B1 (en) * 2009-07-01 2019-05-01 JDS Therapeutics, LLC Chromium complexes as enhancers of brain glucose transporters
AU2014364447A1 (en) * 2013-12-20 2016-08-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod to delay Huntington's disease progression

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1852, JPN6021042082, 2015, pages 1887 - 1894, ISSN: 0004784658 *
DIABETES CARE, vol. 37, JPN6021042086, 2014, pages 1918 - 1923, ISSN: 0004784656 *
FREE RADICAL BIOLOGY AND MEDICINE, vol. 100, JPN6021042084, 2016, pages 153 - 163, ISSN: 0004784657 *

Also Published As

Publication number Publication date
WO2018136635A1 (en) 2018-07-26
SG11201906644YA (en) 2019-08-27
AU2018210165A1 (en) 2019-08-01
KR20190122664A (ko) 2019-10-30
EP3570841A1 (en) 2019-11-27
CA3050104A1 (en) 2018-07-26
IL268008A (en) 2019-09-26
US20190350918A1 (en) 2019-11-21
BR112019014529A2 (pt) 2020-02-27
EA201991716A1 (ru) 2020-02-04
CN110461330A (zh) 2019-11-15
MX2019008535A (es) 2019-12-02
EP3570841A4 (en) 2020-08-19

Similar Documents

Publication Publication Date Title
US20220249515A1 (en) Ganaxolone for use in treating genetic epileptic disorders
US20250025448A1 (en) Methods of increasing tonic inhibition and treating secondary insomnia
JP5289765B2 (ja) 自閉症、強迫神経症、および衝動性の治療のためのメマンチン（ナメンダ）の使用
EP3368080B1 (en) Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
AU2021257754B2 (en) LSD dose identification
JP2008519847A (ja) 運動障害の治療方法
CN112566641A (zh) 治疗和/或预防与年龄相关的神经变性的进展和/或发病的方法和组合物
Egeberg et al. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances
JP2013501805A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
JPWO2007046347A1 (ja) 筋萎縮性側索硬化症患者の運動神経保護用医薬
KR102549684B1 (ko) 신경퇴행성 질병에 대한 치료제
JP2002541198A (ja) 失禁の治療法
JP2020505448A (ja) ハンチントン病の治療のためのＰＰＡＲγアゴニスト
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
JP6830895B2 (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
CN104220074A (zh) 鲁拉西酮新给药方案以及其用于治疗、预防和/或控制至少一种cns病症的用途
US20230390232A1 (en) N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders
JP2001523724A (ja) 運動ニューロン病および脱髄病を治療するためのシチコリン
WO2024211310A1 (en) Methods of dosing spinogenic compounds
TW202539621A (zh) 用於治療巴金森氏症的治療劑
Haider Early Phase Disease Modification Trials with Selisistat & Optical Coherence Tomography as a Biomarker in Huntington's Disease
WO2025162430A1 (zh) 一种药物联用及其在预防或治疗神经退行性疾病中的用途
WO2025163129A1 (en) Acetyl-leucine for treating parkinson´s disease
Malaspina et al. Disorders of the Motor Cells: The Motor Neuron Diseases
JP2025510556A (ja) アルツハイマー型認知症に罹患している患者の治療において使用するためのスフィンゴシン－１－リン酸受容体（ｓ１ｐｒ）モジュレーター

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220530